211 related articles for article (PubMed ID: 31964381)
1. Intrafractional vaginal dilation in anal cancer patients undergoing pelvic radiotherapy (DILANA) - a prospective, randomized, 2-armed phase-II-trial.
Arians N; Häfner M; Krisam J; Lang K; Wark A; Koerber SA; Hommertgen A; Debus J
BMC Cancer; 2020 Jan; 20(1):52. PubMed ID: 31964381
[TBL] [Abstract][Full Text] [Related]
2. Reproducibility and genital sparing with a vaginal dilator used for female anal cancer patients.
Briere TM; Crane CH; Beddar S; Bhosale P; Mok H; Delclos ME; Krishnan S; Das P
Radiother Oncol; 2012 Aug; 104(2):161-6. PubMed ID: 22841019
[TBL] [Abstract][Full Text] [Related]
3. Prospective phase-II-study evaluating postoperative radiotherapy of cervical and endometrial cancer patients using protons - the APROVE-trial.
Arians N; Lindel K; Krisam J; Herfarth K; Krug D; Akbaba S; Oelmann-Avendano J; Debus J
Radiat Oncol; 2017 Nov; 12(1):188. PubMed ID: 29179751
[TBL] [Abstract][Full Text] [Related]
4. Prospective evaluation of acute toxicity and quality of life after IMRT and concurrent chemotherapy for anal canal and perianal cancer.
Han K; Cummings BJ; Lindsay P; Skliarenko J; Craig T; Le LW; Brierley J; Wong R; Dinniwell R; Bayley AJ; Dawson LA; Ringash J; Krzyzanowska MK; Moore MJ; Chen EX; Easson AM; Kassam Z; Cho C; Kim J
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):587-94. PubMed ID: 25194664
[TBL] [Abstract][Full Text] [Related]
5. Intensity-modulated Radiotherapy for Anal Cancer: Dose-Volume Relationship of Acute Gastrointestinal Toxicity and Disease Outcomes.
Ng M; Ho H; Skelton J; Guerrieri M; Guiney M; Chao M; Blakey D; Macleod C; Amor H; Subramanian B; Melven L
Clin Oncol (R Coll Radiol); 2018 Oct; 30(10):634-641. PubMed ID: 30049649
[TBL] [Abstract][Full Text] [Related]
6. Intensity-Modulated Radiotherapy (IMRT) vs Helical Tomotherapy (HT) in Concurrent Chemoradiotherapy (CRT) for Patients with Anal Canal Carcinoma (ACC): an analysis of dose distribution and toxicities.
Yeung R; McConnell Y; Warkentin H; Graham D; Warkentin B; Joseph K; Doll CM
Radiat Oncol; 2015 Apr; 10():92. PubMed ID: 25903798
[TBL] [Abstract][Full Text] [Related]
7. Predictors of Radiation Therapy-Related Gastrointestinal Toxicity From Anal Cancer Dose-Painted Intensity Modulated Radiation Therapy: Secondary Analysis of NRG Oncology RTOG 0529.
Olsen JR; Moughan J; Myerson R; Abitbol A; Doncals DE; Johnson D; Schefter TE; Chen Y; Fisher B; Michalski J; Narayan S; Chang A; Crane CH; Kachnic L
Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):400-408. PubMed ID: 28463160
[TBL] [Abstract][Full Text] [Related]
8. Clinical and treatment factors associated with vaginal stenosis after definitive chemoradiation for anal canal cancer.
Mirabeau-Beale K; Hong TS; Niemierko A; Ancukiewicz M; Blaszkowsky LS; Crowley EM; Cusack JC; Drapek LC; Kovalchuk N; Markowski M; Napolitano B; Nyamwanda J; Ryan DP; Wolfgang J; Kachnic LA; Wo JY
Pract Radiat Oncol; 2015; 5(3):e113-e118. PubMed ID: 25424587
[TBL] [Abstract][Full Text] [Related]
9. CAPIRI-IMRT: a phase II study of concurrent capecitabine and irinotecan with intensity-modulated radiation therapy for the treatment of recurrent rectal cancer.
Cai G; Zhu J; Palmer JD; Xu Y; Hu W; Gu W; Cai S; Zhang Z
Radiat Oncol; 2015 Feb; 10():57. PubMed ID: 25889149
[TBL] [Abstract][Full Text] [Related]
10. Volumetric intensity-modulated arc therapy vs. 3-dimensional conformal radiotherapy for primary chemoradiotherapy of anal carcinoma: Effects on treatment-related side effects and survival.
Weber HE; Dröge LH; Hennies S; Herrmann MK; Gaedcke J; Wolff HA
Strahlenther Onkol; 2015 Nov; 191(11):827-34. PubMed ID: 26050046
[TBL] [Abstract][Full Text] [Related]
11. [Management of locally advanced anal canal carcinoma with modulated arctherapy and concurrent chemotherapy].
Troussier I; Huguet F; Servagi-Vernat S; Benahim C; Khalifa J; Darmon I; Ortholan C; Krebs L; Dejean C; Fenoglietto P; Vieillot S; Bensadoun RJ; Thariat J
Cancer Radiother; 2015 Apr; 19(2):127-38. PubMed ID: 25770884
[TBL] [Abstract][Full Text] [Related]
12. Chemoradiation in female patients with anal cancer: Patient-reported outcome of acute and chronic side effects.
Koerber SA; Seither B; Slynko A; Haefner MF; Krug D; Liermann J; Adeberg S; Herfarth K; Debus J; Sterzing F
Tumori; 2019 Apr; 105(2):174-180. PubMed ID: 30484384
[TBL] [Abstract][Full Text] [Related]
13. Outcomes after intensity-modulated compared with 3-dimensional conformal radiotherapy with chemotherapy for squamous cell carcinoma of the anal canal.
Agarwal MS; Hitchcock KE; Morris CG; George TJ; Mendenhall WM; Zlotecki RA
Curr Oncol; 2019 Aug; 26(4):e515-e521. PubMed ID: 31548820
[TBL] [Abstract][Full Text] [Related]
14. Dose escalated intensity modulated radiotherapy in the treatment of cervical cancer.
Cihoric N; Tsikkinis A; Tapia C; Aebersold DM; Zlobec I; Lössl K
Radiat Oncol; 2015 Nov; 10():240. PubMed ID: 26597282
[TBL] [Abstract][Full Text] [Related]
15. Dosimetric Predictors of Radiation-Induced Vaginal Stenosis After Pelvic Radiation Therapy for Rectal and Anal Cancer.
Son CH; Law E; Oh JH; Apte AP; Yang TJ; Riedel E; Wu AJ; Deasy JO; Goodman KA
Int J Radiat Oncol Biol Phys; 2015 Jul; 92(3):548-54. PubMed ID: 25936810
[TBL] [Abstract][Full Text] [Related]
16. ROAR-A: re-optimization based Online Adaptive Radiotherapy of anal cancer, a prospective phase II trial protocol.
Storm KS; Åström LM; Sibolt P; Behrens CP; Persson GF; Serup-Hansen E
BMC Cancer; 2024 Mar; 24(1):374. PubMed ID: 38528456
[TBL] [Abstract][Full Text] [Related]
17. Dosimetric predictors of acute hematologic toxicity during concurrent intensity-modulated radiotherapy and chemotherapy for anal cancer.
Franco P; Ragona R; Arcadipane F; Mistrangelo M; Cassoni P; Rondi N; Morino M; Racca P; Ricardi U
Clin Transl Oncol; 2017 Jan; 19(1):67-75. PubMed ID: 27037814
[TBL] [Abstract][Full Text] [Related]
18. Irradiation of anatomically defined pelvic subsites and acute hematologic toxicity in anal cancer patients undergoing chemoradiation.
Rose B; Mitra D; Hong TS; Jee KW; Niemierko A; Drapek LN; Blaszkowsky LS; Allen JN; Murphy JE; Clark JW; Ryan DP; Wo JY
Pract Radiat Oncol; 2017; 7(5):e291-e297. PubMed ID: 28462895
[TBL] [Abstract][Full Text] [Related]
19. Hypofractionated simultaneous integrated boost (IMRT-SIB) with pelvic nodal irradiation and concurrent androgen deprivation therapy for high-risk prostate cancer: results of a prospective phase II trial.
Magli A; Moretti E; Tullio A; Giannarini G; Tonetto F; Urpis M; Crespi M; Foti C; Prisco A; Polsinelli M; De Giorgi G; Bravo G; Scalchi P; Trovò M
Prostate Cancer Prostatic Dis; 2018 Jun; 21(2):269-276. PubMed ID: 29520019
[TBL] [Abstract][Full Text] [Related]
20. Manifestation pattern of early-late vaginal morbidity after definitive radiation (chemo)therapy and image-guided adaptive brachytherapy for locally advanced cervical cancer: an analysis from the EMBRACE study.
Kirchheiner K; Nout RA; Tanderup K; Lindegaard JC; Westerveld H; Haie-Meder C; Petrič P; Mahantshetty U; Dörr W; Pötter R
Int J Radiat Oncol Biol Phys; 2014 May; 89(1):88-95. PubMed ID: 24725693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
